THARIMMUNE INC (THAR)

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Friday's after hours session: top gainers and losers

After hours stock analysis on 2024-12-06: top gainers and losers in today's session.

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

THAR Stock Earnings: Tharimmune Reported Results for Q2 2024

Tharimmune just reported results for the second quarter of 2024.

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

Tharimmune Announces $2.08 Million Private Placement

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune to Present at 2024 BIO International Convention

Why Is Verastem (VSTM) Stock Down 62% Today?

Verastem stock is down on Friday with heavy trading of VSTM shares alongside its latest pancreatic cancer clinical trial safety data.

Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?

Sensei Biotherapeutics stock is falling on Friday as SNSE investors are unimpressed by its latest clinical trial data.

Why Is Tharimmune (THAR) Stock Moving Today?

Tharimmune stock is on the move Friday as investors prepare for a reverse split of THAR shares after markets close today.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!

Tharimmune Announces 1-for-15 Reverse Stock Split

THAR Stock Earnings: Tharimmune Reported Results for Q4 2023

Tharimmune just reported results for the fourth quarter of 2023.